Reservoir Neuroscience Inc. has disclosed prostaglandin E2 receptor EP2 subtype (PTGER2; EP2) antagonists reported to be useful for the treatment of inflammation.
Nanchang Helioeast Technology Co. Ltd. has patented oxa-spirocyclic compounds acting as lysine-specific histone demethylase 1A (KDM1A; LSD1) inhibitors and reported to be useful for the treatment of acute myeloid leukemia.
Medshine Discovery Inc. has synthesized nonreceptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of psoriasis, inflammatory bowel disease and systemic lupus erythematosus.
Hangzhou Innogate Pharma Co. Ltd. has identified kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer and viral infections.
Coherent Biopharma Ltd. has divulged peptide-drug conjugates comprising cytotoxic drug covalently linked to folate receptor α (FOLR1; FR- α)-targeting moiety through linker reported to be useful for the treatment of cancer and metabolic, immunological and neurological disorders.
Jazz Pharmaceuticals plc has patented sulfonamides acting as orexin OX2 receptor agonists reported to be useful for the treatment of hypersomnia, narcolepsy and sleep disorders.
Debiopharm International SA has identified enoyl-(acyl-carrier protein) reductase FabI (Acinetobacter baumannii) inhibitors reported to be useful for the treatment of bacterial infections and hospital-acquired pneumonia.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has presented HBeAg (hepatitis B virus; HBV) and/or HBsAg (HBV) secretion inhibitors reported to be useful for the treatment of HBV infections.
National Institute of Pharmaceutical R&D Co. Ltd. has discovered compounds with ability to capture reactive carbonyl species reported to be useful for the treatment of eye disorders, among others.
RSS